RA
KURA icon

Rosalind Advisors’s Kura Oncology KURA Stock Holding History

Rosalind Advisors’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.1M Hold
100,000
– – 0.41% 26
2026
Q1 		$813K Hold
100,000
– – 0.33% 34
2025
Q4 		$1.04M Hold
100,000
– – 0.37% 32
2025
Q3 		$885K Hold
100,000
– – 0.3% 33
2025
Q2 		$577K Hold
100,000
– – 0.27% 30
2025
Q1 		$660K Buy
+100,000
New +$779K 0.32% 29

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Rosalind Advisors's KURA Position: Q2 2026 in Review

Rosalind Advisors held its Kura Oncology (KURA) position steady in Q2 2026 at 100,000 shares worth $1.1M. The position accounts for 0.41% of the portfolio, ranked #26.

Rosalind Advisors first reported a position in KURA in Q1 2025 and has held it in 6 quarters since. 220 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • Rosalind Advisors held 100,000 shares of Kura Oncology worth $1.1M as of Q2 2026.
  • Rosalind Advisors left its Kura Oncology share count unchanged in Q2 2026.
  • Kura Oncology made up 0.41% of Rosalind Advisors's portfolio in Q2 2026, its #26 holding.
  • Rosalind Advisors first reported a position in Kura Oncology in Q1 2025 and has held it in 6 quarters since.
  • 220 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on Rosalind Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.